▁to ▁be ▁a ▁success ". ▁▁ ▁Before ▁the ▁United ▁States ▁Congress ▁en act ed ▁the ▁O DA ▁in ▁ 1 9 8 3 , ▁only ▁ 3 8 ▁dru gs ▁were ▁approved ▁in ▁the ▁USA ▁specifically ▁to ▁treat ▁or phan ▁dise ases . ▁ ▁In ▁the ▁USA , ▁from ▁January ▁ 1 9 8 3 ▁to ▁June ▁ 2 0 0 4 , ▁the ▁Office ▁of ▁Or phan ▁Product s ▁Development ▁ 2 4 9 ▁or phan ▁dru gs ▁received ▁market ing ▁authorization ▁and ▁granted ▁ 1 , 1 2 9 ▁different ▁or phan ▁drug ▁design ations , ▁compared ▁to ▁fewer ▁than ▁ten ▁such ▁products ▁in ▁the ▁de cade ▁prior ▁to ▁ 1 9 8 3 . ▁ ▁From ▁ 1 9 8 3 ▁until ▁May ▁ 2 0 1 0 , ▁the ▁F DA ▁approved ▁ 3 5 3 ▁or phan ▁dru gs ▁and ▁granted ▁or phan ▁design ations ▁to ▁ 2 , 1 1 6 ▁comp ounds . ▁ ▁As ▁of ▁ 2 0 1 0 , ▁ 2 0 0 ▁of ▁the ▁roughly ▁ 7 , 0 0 0 ▁officially ▁designated ▁or phan ▁dise ases ▁have ▁become ▁treat able . ▁ ▁Crit ics ▁have ▁question ed ▁whether ▁or phan ▁drug ▁legisl ation ▁was ▁the ▁real ▁cause ▁of ▁this ▁increase , ▁claim ing ▁that ▁many ▁of ▁the ▁new ▁dru gs ▁were ▁for ▁dis orders ▁which ▁were ▁already ▁being ▁research ed ▁anyway , ▁and ▁would ▁have ▁had ▁dru gs ▁developed ▁regardless ▁of ▁the ▁legisl ation , ▁and ▁whether ▁the ▁O DA ▁has